Haleon PLC Sponsored ADR

HLN Healthcare Drug Manufacturers Specialty & Generic

Haleon PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $14.5 billion, up 1.33% from fiscal 2024.

9.13 0.10 −1.08%
Market cap
$40.2B
P/E
20.5×
Fwd P/E
16.5×
Dividend yield
2.16%
F-score
8/9
Altman Z
3.04
Beneish M
−2.60
Dividend safety
63/100

Haleon PLC Sponsored ADR (HLN) P/S ratio

Alert me on P/S ratio

As of 5 November 2026, Haleon PLC Sponsored ADR (HLN) trades at a P/S ratio of 2.3×. Over the past ten years it has ranged from 0.0× (March 2024) to 2.9× (June 2025); the current reading is higher than 43% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 2.1× and below the Healthcare sector median of 3.5×.

P/S ratio, daily

Embed this chart

Annual newest first

Period P/S ratio Change
FY2025 2.6× 5.98%
FY2024 2.4× —
FY2023 0.0× —
FY2022 0.0× —
FY2021 0.0× —
FY2020 0.0× —
FY2019 0.0× —

Quarterly newest first

Period P/S ratio Change
Sep 2024 2.7× 26.94%
Mar 2024 2.1× —
Sep 2023 0.0× —
Jun 2023 0.0× —
1 more quarters

Against its own ten years

Low 0.0× High 2.9×
Ten-year median 2.4×
Current reading's percentile 43

P/S ratio against peers

Company P/S ratio
VTRS Viatris Inc. compare 1.5×
TAK Takeda Pharmaceutical Co. compare 2.2×
HLN Haleon PLC Sponsored ADR 2.3×
ELAN Elanco Animal Health Incorporated compare 2.4×
TEVA Teva Pharmaceutical Industries Ltd. compare 2.8×
ZTS Zoetis Inc. compare 3.6×
RDY Dr. Reddy's Laboratories Ltd compare 3.6×
NBIX Neurocrine Biosciences, Inc. compare 4.4×
UTHR United Therapeutics Corporation compare 7.6×
Drug Manufacturers Specialty & Generic industry median 2.1×
Healthcare sector median 3.5×
Market median 1.9×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

More on HLN